Tursi, A.; Pellegrino, R.; Mocci, G.; Savarino, E.V.; Maconi, G.; Elisei, W.; Gravina, A.G.; Italian Network for Inflammatory Bowel Diseases (IN-IBD).
Sex-Specific Real-Life Profiling in Vedolizumab, Ustekinumab, and Tofacitinib Effectiveness in Ulcerative Colitis. J. Clin. Med. 2025, 14, 7476.
https://doi.org/10.3390/jcm14217476
AMA Style
Tursi A, Pellegrino R, Mocci G, Savarino EV, Maconi G, Elisei W, Gravina AG, Italian Network for Inflammatory Bowel Diseases (IN-IBD).
Sex-Specific Real-Life Profiling in Vedolizumab, Ustekinumab, and Tofacitinib Effectiveness in Ulcerative Colitis. Journal of Clinical Medicine. 2025; 14(21):7476.
https://doi.org/10.3390/jcm14217476
Chicago/Turabian Style
Tursi, Antonio, Raffaele Pellegrino, Giammarco Mocci, Edoardo Vincenzo Savarino, Giovanni Maconi, Walter Elisei, Antonietta Gerarda Gravina, and Italian Network for Inflammatory Bowel Diseases (IN-IBD).
2025. "Sex-Specific Real-Life Profiling in Vedolizumab, Ustekinumab, and Tofacitinib Effectiveness in Ulcerative Colitis" Journal of Clinical Medicine 14, no. 21: 7476.
https://doi.org/10.3390/jcm14217476
APA Style
Tursi, A., Pellegrino, R., Mocci, G., Savarino, E. V., Maconi, G., Elisei, W., Gravina, A. G., & Italian Network for Inflammatory Bowel Diseases (IN-IBD).
(2025). Sex-Specific Real-Life Profiling in Vedolizumab, Ustekinumab, and Tofacitinib Effectiveness in Ulcerative Colitis. Journal of Clinical Medicine, 14(21), 7476.
https://doi.org/10.3390/jcm14217476